What MIM Fertility does

MIM Fertility is a Warsaw, Poland-based Software as a Medical Device (SaMD) company founded in 2019 that develops AI-powered clinical decision support tools for fertility clinics and IVF centers. The company's three core products — FOLLISCAN (ovarian follicle monitoring from 2D/3D ultrasound), EMBRYOAID (5-day embryo assessment from static images and time-lapse video), and ENDOSCAN (endometrial receptivity measurement, currently Research Use Only) — collectively address the three pivotal stages of an IVF cycle: stimulation monitoring, embryo selection, and transfer timing. The underlying technology uses deep learning and computer vision, with EMBRYOAID trained on 15.2 million image frames, 86,000 embryos, and 6,500 confirmed transfer outcomes sourced from 70 IVF clinics worldwide.

The platform is hardware-independent and cloud-based, integrating with incumbent clinic infrastructure including DICOM-compatible ultrasound machines, Esco Medical's MIRI time-lapse incubators, Hamilton Thorne's LYKOS laser systems, and EMR systems via API. FOLLISCAN holds FDA 510(k) clearance and EU MDR Class IIa certification; EMBRYOAID is EU MDR Class I, ANVISA (Brazil), and TGA (Australia) cleared. MIM Fertility is ISO 13485 certified and GDPR compliant, with data stored in AWS Frankfurt.

The company monetizes via annual SaaS subscriptions sold to enterprise fertility clinics through direct field sales, quote-based demo requests, OEM partnerships with equipment manufacturers, and conference-led demand generation at ASRM and ESHRE. Customers span at least 12 countries including the US, UK, EU member states, Brazil, Australia, and Indonesia, with named logos such as Advanced Fertility Center of Texas, CEGYR, Fertility Centers of Illinois, FAKIH IVF, and Nusraya Fertility Center. The company has raised $2 million in seed funding (December 2023) from Tangent Line Ventures and Peleton, employs 51–100 people, and is led by co-founders Ula Sankowska (CEO) and Piotr Wygocki (CTO).

Name

MIM Fertility

Legal name

MIM Fertility Sp. z o.o.

Website

https://mimfertility.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

MIM Fertility is a Warsaw-based AI medical device company that develops AI-powered clinical decision support software (FOLLISCAN, EMBRYOAID, ENDOSCAN) for IVF clinics and fertility specialists globally, using computer vision to automate follicle monitoring, embryo assessment, and endometrial receptivity measurement.

Ownership category

akta.pro rank

Product category

Reproductive Medicine AI Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)

Keywords

• Fertility AI software
• IVF clinical decision support
• Embryo assessment AI
• Follicular monitoring software
• Reproductive medicine AI

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. SaaS Medical Device Software Subscriptions: The company operates as a Software as a Medical Device (SaMD) provider, offering AI-powered clinical decision support tools to fertility clinics. Products are certified medical devices (FOLLISCAN: CE Class IIa, FDA 510(k); EMBRYOAID: Class I) sold as subscriptions to IVF clinics for use in clinical workflows.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MIM Fertility develops and sells AI-powered medical device software (SaMD) for fertility clinics and IVF centers. Its portfolio includes FOLLISCAN (AI ovarian follicular monitoring from ultrasound), EMBRYOAID (AI embryo assessment from images and time-lapse video), and ENDOSCAN (AI endometrial receptivity measurement). Products are cloud-based, hardware-independent, and sold as subscriptions to clinical fertility teams for use in IVF workflows.

Product overview

MIM Fertility offers a portfolio of three AI-powered medical device software (SaMD) products for IVF care: FOLLISCAN (ovarian follicular monitoring), EMBRYOAID (embryo assessment), and ENDOSCAN (endometrial receptivity). All three are cloud-based, web-accessible tools that integrate with existing clinic ultrasound machines, microscopes, time-lapse incubators, and EMR systems. The products work together holistically to address infertility throughout the IVF journey—from follicle monitoring during stimulation, to embryo selection for transfer, to endometrial assessment for optimal timing. MIM Fertility positions its AI as a decision-support 'copilot' for fertility professionals, not a replacement for clinical judgment.

Differentiator

Problem solved

Functional benefit

Brands

• FOLLISCAN: AI/ML-Powered Ovarian Follicular Monitoring Tool with 97% accuracy in measurement, works on both 2D and 3D ultrasounds, US machine and EMR integration.
• EMBRYOAID
• ENDOSCAN

Products and services

• FOLLISCAN AI-powered Software as a Medical Device (SaMD) that analyzes 2D and 3D transvaginal ultrasound scans to automatically detect, count, categorize, and measure ovarian follicles. Achieves 97% measurement accuracy and 93% F-score for large follicles (≥10 mm). CE certified under EU MDR Class IIa and FDA 510(k) cleared. Designed for fertility specialists to standardize stimulation protocol decisions during IVF cycles.
• EMBRYOAID

Quantifiable outcome

• FOLLISCAN achieves 97% accuracy in follicle measurement and 93% F-score for large follicles (≥10 mm)
• +4 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability9 records

Feature5 records

Partnerships

One partnership is on record.

• Esco MedicalcoreTechnology or Integration · 10 April 2026Formal partnership integrating MIM Fertility's EMBRYOAID AI embryo assessment tool with Esco Medical's MIRI time-lapse incubator platform. The integration enables clinics to access AI-assisted embryo assessment within the MIRI time-lapse environment. The partnership covers EU, UK, Brazil, and Australia markets where EMBRYOAID holds regulatory clearances. Effective April 10, 2026.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Fairtility: Fairtility offers CHLOE, an AI embryo assessment platform used by IVF clinics worldwide. It is a direct competitor to EMBRYOAID for AI-driven embryo scoring and ranking.
• AIVF: AIVF builds AI software for IVF clinics, including embryo evaluation and clinic workflow optimization. It overlaps with MIM Fertility's clinical-decision-support and workflow-efficiency positioning.
• Alife Health: Alife Health develops AI-driven decision support software for IVF clinics, including embryo evaluation and stimulation optimization — directly competing with MIM Fertility's EMBRYOAID and FOLLISCAN across the same fertility-clinic customer base.

Broad incumbents

• Vitrolife: Vitrolife is a global IVF media, consumables, and time-lapse incubation provider with its own EmbryoScope AI ecosystem. It competes with MIM as a broader incumbent in the IVF lab stack that can internalize or bundle AI functionality.
• Hamilton Thorne: Hamilton Thorne manufactures laser systems, microscopes, and other ART equipment used in IVF labs. It is both a partner (LYKOS integration) and a broad incumbent whose installed base and capital give it the option to compete directly with MIM.
• Esco Medical: Esco Medical manufactures the MIRI time-lapse incubator family and is MIM Fertility's deepest integration partner. As an incumbent equipment vendor with global reach, Esco represents both a distribution channel and a potential competitive threat if it builds in-house AI.
• Genea Biomedx: Genea Biomedx develops IVF lab instruments and software (e.g., Geri time-lapse incubator). Its combined hardware-plus-software offering competes with MIM's full-journey suite for IVF clinic budgets and standardization contracts.

Emerging players

• Presagen / Life Whisperer: Life Whisperer (a Presagen product) applies AI to embryo and oocyte assessment for IVF clinics. It is an emerging AI fertility player with overlapping embryo-selection functionality targeting similar IVF clinic customers.
• TMRW Life Sciences: TMRW provides automated cryo-storage and digital specimen management for IVF clinics. It is an adjacent emerging player — not a direct embryo-assessment competitor — but competes for the same fertility-clinic technology budget and modernization agenda.

Regional players

• Ovation Fertility: Ovation Fertility is a US-based network of fertility clinics and labs that has invested in proprietary IVF lab technology and AI tools. It is a regional player that competes in the US IVF market where MIM Fertility is now expanding post-FDA clearance.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@MIMFertility
• LinkedInlinkedin.com/company/mim-fertility
• Instagraminstagram.com/mim.fertility

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIM Fertility